The estimated Net Worth of Lance Willsey is at least $19.6 Million dollars as of 12 May 2022. Lance Willsey owns over 40,000 units of Exelixis Inc stock worth over $12,367,371 and over the last 21 years he sold EXEL stock worth over $6,747,900. In addition, he makes $445,780 as Independent Director at Exelixis Inc.
Lance has made over 19 trades of the Exelixis Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of EXEL stock worth $125,200 on 12 May 2022.
The largest trade he's ever made was exercising 106,142 units of Exelixis Inc stock on 4 December 2020 worth over $617,746. On average, Lance trades about 20,072 units every 99 days since 2003. As of 12 May 2022 he still owns at least 464,415 units of Exelixis Inc stock.
You can see the complete history of Lance Willsey stock trades at the bottom of the page.
Dr. Lance Willsey M.D. serves as Independent Director of the Company. Lance Willsey, M.D., has been a director since April 1997. Dr. Willsey was a founding partner of DCF Capital, a hedge fund focused on investing in the life sciences, from July 1998 to March 2002, and currently is a consultant to institutional investors in the field of oncology. Since 2000, Dr. Willsey has served on the Visiting Committee of the Department of Genitourinary Oncology at the Dana-Farber Cancer Institute at Harvard Medical School. From July 1997 to July 1998, Dr. Willsey served on the Staff Department of Urologic Oncology at the Dana-Farber Cancer Institute. From July 1996 to July 1997, Dr. Willsey served on the Staff Department of Urology at Massachusetts General Hospital at Harvard University School of Medicine, where he was a urology resident from July 1992 to July 1996. From 2000 to 2010, Dr. Willsey served a member of the board of directors of Exact Sciences Corporation, a publicly held molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. Dr. Willsey holds a B.S. in Physiology from Michigan State University and an M.S. in Biology and an M.D., both from Wayne State University.
As the Independent Director of Exelixis Inc, the total compensation of Lance Willsey at Exelixis Inc is $445,780. There are 18 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Lance Willsey is 58, he's been the Independent Director of Exelixis Inc since 1997. There are 14 older and 7 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Lance's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: